In SURMOUNT-5, a head-to-head trial of the injections, mean weight change was −13.7% on semaglutide (Wegovy) and −20.2% on tirzepatide (Zepbound) over 72 weeks. Prices and approved uses vary by brand and dose.
| Compare | Semaglutide | Tirzepatide |
|---|---|---|
| Brands | Mounjaro, Zepbound GIP/GLP-1 | |
| Route & frequency | Subcutaneous injection (Ozempic, Wegovy); oral tablet (Rybelsus, oral Ozempic, Wegovy pill) Once weekly (injectable); once daily (oral) |
Wegovy injection vs Zepbound
Adults with obesity, or overweight with a weight-related condition, without diabetes.
751 participants · 72 weeks · Randomized, open-label
Mean weight change (% of body weight)
Treatment-regimen analysis, regardless of treatment adherence.
| Treatment & dose | Change |
|---|---|
| Semaglutide (Wegovy)1.7 or 2.4 mg weekly injection | −13.7% |
Lowest tracked quotes for FDA-approved products, selected separately for each price basis. Entry prices may refer to different brands or formulations. Supply periods, eligibility, refill deadlines, and additional fees can change what you pay.
| Compare | Semaglutide | Tirzepatide |
|---|---|---|
| Advertised entry price | $149-$299/mo Wegovy pill (oral semaglutide) via GoodRx GoodRx by dose; Novo Nordisk's self-pay price through a GoodRx coupon Third-party reported price |
Each result belongs to its own trial, population, dose, and analysis. Weight loss, HbA1c change, and adverse events may come from different studies even within one ingredient. These are study averages, not predictions of your result.
| Compare | Semaglutide | Tirzepatide |
|---|---|---|
| Weight change | −14.9% (-14.9% at 68 wks · STEP 1 · 2.4 mg weekly (Wegovy)) -14.9% at 68 wks STEP 12.4 mg weekly (Wegovy) Accounts for treatment discontinuation |
Indications depend on the brand and formulation. Read the product-specific indications and prescribing information in the full record.
769 registered ingredient studies. Count checked . Research activity, not a measure of evidence quality.
Open full recordIndications depend on the brand and formulation. Read the product-specific indications and prescribing information in the full record.
296 registered ingredient studies. Count checked . Research activity, not a measure of evidence quality.
Open full recordCompare the named products and price conditions below. A tracked entry quote can be a different brand or formulation from the product studied in a trial. A trial-dose quote applies only to the named product and dose; neither figure is an estimate of your whole treatment cost or an insurance quote.
Direct trials compare the treatments, doses, and participants they studied. Results from separate trials differ in population, duration, dose, and analysis, so their percentages do not establish a treatment ranking. Discuss your medical history and the specific product label with a licensed clinician.
No. FDA shortage records describe national supply reports and covered presentations, not inventory at an individual pharmacy. Unknown status means the data cannot establish a current assessment. Confirm local stock with your pharmacy.
Automated feed checks do not constitute a clinical or editorial review. Sources & methodology
Subcutaneous injection Once weekly |
| FDA shortage report | National reporting does not confirm stock at your pharmacy. Coverage & source records | National reporting does not confirm stock at your pharmacy. Coverage & source records |
|---|
| Tirzepatide (Zepbound)10 or 15 mg weekly injection | −20.2% |
|---|
Tirzepatide produced greater mean weight reduction in this trial. Both groups used their maximum tolerated dose.
This trial did not test Wegovy tablets or Wegovy HD. It was not powered to establish a safety or tolerability advantage. Study averages do not predict an individual's result.
Ozempic injection vs Mounjaro
Adults with type 2 diabetes inadequately controlled with metformin.
1,879 participants · 40 weeks · Randomized, open-label
Mean HbA1c change (percentage points)
Treatment-regimen analysis, regardless of treatment adherence or rescue therapy.
| Treatment & dose | Change |
|---|---|
| Semaglutide (Ozempic)1 mg weekly injection | −1.86 pp |
| Tirzepatide (Mounjaro)5 mg weekly injection | −2.01 pp |
| Tirzepatide (Mounjaro)10 mg weekly injection | −2.24 pp |
| Tirzepatide (Mounjaro)15 mg weekly injection | −2.3 pp |
Each tirzepatide dose lowered HbA1c more than semaglutide 1 mg in this trial.
This trial did not compare Ozempic 2 mg or tablets. HbA1c changes are percentage points, not relative percentages or weight-loss results. Study averages do not predict an individual's result.
$149 per 30 days at this quoted rate
Checked
by dose; Novo Nordisk's self-pay price through a GoodRx coupon
The same oral semaglutide and prices as the NovoCare offer: $149 (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg), per Novo Nordisk's published self-pay ladder. FDA-approved product.
30-day supply
$299-$449/28 days Zepbound KwikPen (multi-dose pen) LillyDirect (Eli Lilly) self-pay cash, by dose ($299 / $399 / $449) ≈ $320.36 per 30 days at this quoted rate Checked Price conditionsself-pay cash, by dose ($299 / $399 / $449) Four weekly doses per pen; pen needles must be purchased separately. $299 at 2.5 mg, $399 at 5 mg, and $449 at higher doses under the Self Pay Journey offer with a refill within 45 days. 28-day supply |
| At the named trial dose | $349/28 days Wegovy pen (standard doses 0.25-2.4 mg) At 2.4 mg NovoCare (Novo Nordisk) Published price at 2.4 mg ≈ $373.93 per 30 days at this quoted rate Checked Price conditionsPublished price at 2.4 mg After the introductory offer, standard doses cost $349 per box of four weekly pens. Wegovy HD (7.2 mg) is $399. Eligibility and restrictions apply. One price for every standard dose (0.25-2.4 mg). 28-day supply | $449/28 days Zepbound KwikPen (multi-dose pen) At 15 mg LillyDirect (Eli Lilly) Published price at 15 mg ≈ $481.07 per 30 days at this quoted rate Checked Price conditionsPublished price at 15 mg Four weekly doses per pen; pen needles must be purchased separately. $299 at 2.5 mg, $399 at 5 mg, and $449 at higher doses under the Self Pay Journey offer with a refill within 45 days. Self Pay Journey price for 7.5-15 mg with a refill within 45 days; otherwise $499 (7.5 mg) or $699 (10-15 mg). Pen needles cost extra. 28-day supply |
|---|
| Explore product prices | All Semaglutide offers | All Tirzepatide offers |
|---|
USD self-pay, not insurance or pharmacy acquisition cost. A trial dose is not a personal dosing recommendation. Compounded offers are shown separately in the offer browser and are not FDA-approved.
The headline is the standard 2.4 mg maintenance dose (Wegovy), the dose used in STEP 1 and one of the permitted doses in SURMOUNT-5. Other doses and formulations have their own trials, including STEP UP and OASIS 4. Their results are not interchangeable.
−20.9% (-20.9% at 72 wks · SURMOUNT-1 · 15 mg weekly (Zepbound)) -20.9% at 72 wks SURMOUNT-115 mg weekly (Zepbound) Accounts for treatment discontinuation Study contextSURMOUNT-1 studied adults with obesity or overweight without diabetes. This result belongs to the 15 mg arm and the treatment-regimen analysis; other doses and analyses have different results. |
| HbA1c change (percentage points) | −1.6 pp (-1.6% at 68 wks · STEP 2 · HbA1c change in percentage points) -1.6 percentage points at 68 wks STEP 2Study contextThe headline is the standard 2.4 mg maintenance dose (Wegovy), the dose used in STEP 1 and one of the permitted doses in SURMOUNT-5. Other doses and formulations have their own trials, including STEP UP and OASIS 4. Their results are not interchangeable. | −2.3 pp (-2.3% at 40 wks · SURPASS-2 · HbA1c change in percentage points) -2.3 percentage points at 40 wks SURPASS-2Study contextSURMOUNT-1 studied adults with obesity or overweight without diabetes. This result belongs to the 15 mg arm and the treatment-regimen analysis; other doses and analyses have different results. |
|---|
| Adverse events | Stopped treatment for adverse events 7% (7.0% vs 3.1% placebo · STEP 1 (2.4 mg, 68 wks, obesity))Reported nausea 44.2% (Nausea in the drug arm · STEP 1 (2.4 mg, 68 wks, obesity))STEP 1 (2.4 mg, 68 wks, obesity) | Stopped treatment for adverse events 6.2% (6.2% vs 2.6% placebo (15 mg) · SURMOUNT-1 (15 mg, 72 wks, obesity))Reported nausea 31% (Nausea in the drug arm · SURMOUNT-1 (15 mg, 72 wks, obesity))SURMOUNT-1 (15 mg, 72 wks, obesity) |
|---|